Bromodomain and hedgehog pathway targets in small cell lung cancer

Gurmeet Kaur, Russell A. Reinhart, Anne Monks, David Evans, Joel Morris, Eric Polley, Beverly A. Teicher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an extremely aggressive cancer that frequently recurs. Twenty-three human SCLC lines were selected representing varied Myc status. Gene expression of lung cancer, stem-like, hedgehog pathway, and notch pathway genes were determined by RT2-PCR array and Exon 1.0 ST array. Etoposide and topotecan concentration response was examined. The IC50's for etoposide and topotecan ranged over nearly 3 logs upon 96hrs exposure to the drugs. Myc status, TOP2A, TOP2B and TOP1 mRNA expression or topoisomerase 1 and topoisomerase 2 protein did not account for the range in the sensitivity to the drugs. γ-secretase inhibitors, RO429097 and PF-03084014, had little activity in the SCLC lines over ranges covering the clinical Cmax concentrations. MYC amplified lines tended to be more sensitive to the bromodomain inhibitor JQ1. The Smo antagonists, erismodegib and vismodegib and the Gli antagonists, HPI1 and SEN-450 had a trend toward greater sensitivity of the MYC amplified line. Recurrent SCLC is among the most recalcitrant cancers and drug development efforts in this cancer are a high priority.

Original languageEnglish (US)
Pages (from-to)225-239
Number of pages15
JournalCancer Letters
Volume371
Issue number2
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Topotecan
Etoposide
HhAntag691
Pharmaceutical Preparations
Neoplasms
Amyloid Precursor Protein Secretases
Inhibitory Concentration 50
Exons
Lung Neoplasms
Gene Expression
Polymerase Chain Reaction
Messenger RNA
Genes
Proteins

Keywords

  • Bromodomain inhibitors
  • Hedgehog inhibitors
  • SCLC
  • SCLC gene expression
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kaur, G., Reinhart, R. A., Monks, A., Evans, D., Morris, J., Polley, E., & Teicher, B. A. (2016). Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Letters, 371(2), 225-239. https://doi.org/10.1016/j.canlet.2015.12.001

Bromodomain and hedgehog pathway targets in small cell lung cancer. / Kaur, Gurmeet; Reinhart, Russell A.; Monks, Anne; Evans, David; Morris, Joel; Polley, Eric; Teicher, Beverly A.

In: Cancer Letters, Vol. 371, No. 2, 01.01.2016, p. 225-239.

Research output: Contribution to journalArticle

Kaur, G, Reinhart, RA, Monks, A, Evans, D, Morris, J, Polley, E & Teicher, BA 2016, 'Bromodomain and hedgehog pathway targets in small cell lung cancer', Cancer Letters, vol. 371, no. 2, pp. 225-239. https://doi.org/10.1016/j.canlet.2015.12.001
Kaur, Gurmeet ; Reinhart, Russell A. ; Monks, Anne ; Evans, David ; Morris, Joel ; Polley, Eric ; Teicher, Beverly A. / Bromodomain and hedgehog pathway targets in small cell lung cancer. In: Cancer Letters. 2016 ; Vol. 371, No. 2. pp. 225-239.
@article{0af78926bf374596a2e98b74f91718a7,
title = "Bromodomain and hedgehog pathway targets in small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is an extremely aggressive cancer that frequently recurs. Twenty-three human SCLC lines were selected representing varied Myc status. Gene expression of lung cancer, stem-like, hedgehog pathway, and notch pathway genes were determined by RT2-PCR array and Exon 1.0 ST array. Etoposide and topotecan concentration response was examined. The IC50's for etoposide and topotecan ranged over nearly 3 logs upon 96hrs exposure to the drugs. Myc status, TOP2A, TOP2B and TOP1 mRNA expression or topoisomerase 1 and topoisomerase 2 protein did not account for the range in the sensitivity to the drugs. γ-secretase inhibitors, RO429097 and PF-03084014, had little activity in the SCLC lines over ranges covering the clinical Cmax concentrations. MYC amplified lines tended to be more sensitive to the bromodomain inhibitor JQ1. The Smo antagonists, erismodegib and vismodegib and the Gli antagonists, HPI1 and SEN-450 had a trend toward greater sensitivity of the MYC amplified line. Recurrent SCLC is among the most recalcitrant cancers and drug development efforts in this cancer are a high priority.",
keywords = "Bromodomain inhibitors, Hedgehog inhibitors, SCLC, SCLC gene expression, Small cell lung cancer",
author = "Gurmeet Kaur and Reinhart, {Russell A.} and Anne Monks and David Evans and Joel Morris and Eric Polley and Teicher, {Beverly A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2015.12.001",
language = "English (US)",
volume = "371",
pages = "225--239",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Bromodomain and hedgehog pathway targets in small cell lung cancer

AU - Kaur, Gurmeet

AU - Reinhart, Russell A.

AU - Monks, Anne

AU - Evans, David

AU - Morris, Joel

AU - Polley, Eric

AU - Teicher, Beverly A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Small cell lung cancer (SCLC) is an extremely aggressive cancer that frequently recurs. Twenty-three human SCLC lines were selected representing varied Myc status. Gene expression of lung cancer, stem-like, hedgehog pathway, and notch pathway genes were determined by RT2-PCR array and Exon 1.0 ST array. Etoposide and topotecan concentration response was examined. The IC50's for etoposide and topotecan ranged over nearly 3 logs upon 96hrs exposure to the drugs. Myc status, TOP2A, TOP2B and TOP1 mRNA expression or topoisomerase 1 and topoisomerase 2 protein did not account for the range in the sensitivity to the drugs. γ-secretase inhibitors, RO429097 and PF-03084014, had little activity in the SCLC lines over ranges covering the clinical Cmax concentrations. MYC amplified lines tended to be more sensitive to the bromodomain inhibitor JQ1. The Smo antagonists, erismodegib and vismodegib and the Gli antagonists, HPI1 and SEN-450 had a trend toward greater sensitivity of the MYC amplified line. Recurrent SCLC is among the most recalcitrant cancers and drug development efforts in this cancer are a high priority.

AB - Small cell lung cancer (SCLC) is an extremely aggressive cancer that frequently recurs. Twenty-three human SCLC lines were selected representing varied Myc status. Gene expression of lung cancer, stem-like, hedgehog pathway, and notch pathway genes were determined by RT2-PCR array and Exon 1.0 ST array. Etoposide and topotecan concentration response was examined. The IC50's for etoposide and topotecan ranged over nearly 3 logs upon 96hrs exposure to the drugs. Myc status, TOP2A, TOP2B and TOP1 mRNA expression or topoisomerase 1 and topoisomerase 2 protein did not account for the range in the sensitivity to the drugs. γ-secretase inhibitors, RO429097 and PF-03084014, had little activity in the SCLC lines over ranges covering the clinical Cmax concentrations. MYC amplified lines tended to be more sensitive to the bromodomain inhibitor JQ1. The Smo antagonists, erismodegib and vismodegib and the Gli antagonists, HPI1 and SEN-450 had a trend toward greater sensitivity of the MYC amplified line. Recurrent SCLC is among the most recalcitrant cancers and drug development efforts in this cancer are a high priority.

KW - Bromodomain inhibitors

KW - Hedgehog inhibitors

KW - SCLC

KW - SCLC gene expression

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84962019891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962019891&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.12.001

DO - 10.1016/j.canlet.2015.12.001

M3 - Article

C2 - 26683772

AN - SCOPUS:84962019891

VL - 371

SP - 225

EP - 239

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -